ClinicalTrials.gg
CompletedNCT04699812Updated Aug 24, 2022Results posted

Atrial Fibrillation Algorithms Clinical Validation Study

An interventional study of ELECTROCARDIOGRAM (ECG) PATCH WEAR in Atrial Fibrillation, sponsored by Apple Inc.. Completed at 4 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-24.

Sponsored by Apple Inc. · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
573
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
122nd of 679
573 · median 127
Started
2020
with 56 others
No phase
405 of 993
67 open now
Registered
698th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 122nd largest by enrollment of the 679 interventional ones that give a count, is one of 57 that started in 2020, is one of 405 with no phase, and was the 698th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.

Read the detailed description

The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • CARDIOVASCULAR DISEASES
  • HEART DISEASES
  • ARRHYTHMIA
  • CARDIAC
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to read, understand, and provide written
  2. Willing and able to participate in the study procedures as described in the consent form
  3. Be 22 years of age and older
  4. Able to communicate effectively with and follow instructions from the study staff
  5. Able to wear the wrist device for duration of study participation
  6. For Cohort 1, have no known medical history of AF
  7. For Cohort 2, have no known medical history of AF and active diagnosis of at least one of the following arrhythmias within the past 2 years:

    1. Frequent PACs, defined as at least 1% of total beats of atrial ectopic beats by 24-48 hour Holter, ambulatory monitor, or implantable loop recorder)
    2. Frequent PVCs, defined as at least 1% of total beats of ventricular ectopic beats by 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
    3. SVT, which will include atrial tachycardia, atrioventricular nodal re-entrant tachycardia, atrioventricular re-entrant tachycardia by 12-lead ECG or 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
    4. NSVT, defined as three or more consecutive ventricular beats at a rate of at least 100 beats per minute and lasting no more than 30 seconds, by 12-lead ECG or 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
  8. For Cohorts 3 and 4, have a known diagnosis of AF at the time of screening (confirmed by electronic medical record (EMR) or self-report) and have had a recent episode of AF, or confirmed AF on ECG, in the past 12 months
  9. For Cohort 4, have a known diagnosis of permanent AF at the time of screening (confirmed by EMR or self-report) and have had a recent episode of AF, or confirmed AF on ECG, in the past 12 months
  10. Meet additional binning based on demographics.

Exclusion criteria

Exclusion Criteria:

  1. Physical disability that precludes safe and adequate testing
  2. Mental impairment resulting in limited ability to cooperate
  3. Known uncontrolled medical conditions, such as (but not limited to) significant anemia, important electrolyte imbalance and untreated or uncontrolled thyroid disease
  4. Open wound(s) on the wrist and/or forearm
  5. Tattoos, large moles, or scars on the wrist at the wrist device location
  6. Skin conditions on either wrist that would preclude subject from wearing a wristband on either wrist
  7. Known allergy or sensitivity to medical adhesives, isopropyl alcohol, wristbands, or patch
  8. Medical history or physical assessment finding that makes the subject inappropriate for participation according to investigator(s)
  9. Participation in a previous study that used a wrist-worn sensor device with a simultaneous ECG reference patch
  10. Implantable cardiac devices such as a Pacemaker or Implantable Cardioverter Defibrillator
  11. hand tremors, as judged by the investigator
  12. Acute illness including COVID and other respiratory illnesses
  13. Subjects with known history of AF on rhythm control medications with history of complete AF rhythm control (i.e history of zero AF burden) will be excluded from Cohorts 3 and 4
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
573 participants (actual)

Study arms

  • Other
    COHORT 1

    This will include subjects with no known history of AF

    Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR

  • Other
    COHORT 2

    This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)

    Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR

  • Other
    COHORT 3

    This will include subjects with known history of paroxysmal, persistent, or chronic AF

    Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR

  • Other
    COHORT 4

    Will include subjects with permanent AF

    Device: ELECTROCARDIOGRAM (ECG) PATCH WEAR

Interventions

  • DeviceELECTROCARDIOGRAM (ECG) PATCH WEAR

    ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION

    Also known as: CARDEASOLO

06

What researchers measure

Primary outcomes

  1. SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]

    Sensitivity of the irregular rhythm notification for the identification of persons with AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Sensitivity is defined as the percentage of subjects exhibiting AF on the ambulatory ECG who also received an irregular rhythm notification concordant with at least one episode of AF.

    Time frame: 13 DAYS

  2. SPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF]

    Specificity of the lack of irregular rhythm notification for the identification of persons without AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Specificity is defined as the percentage of subjects not exhibiting AF on the ambulatory ECG who also did not receive any irregular rhythm notifications.

    Time frame: 13 DAYS

  3. WEEKLY ATRIAL FIBRILLATION BURDEN FEATURE ESTIMATE [AFBF]

    Weekly AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during wrist device wear over the prior 7 consecutive days. The weekly AF burden was estimated by both the reference device and the algorithm and reported using the Bland-Altman limits of Agreement.

    Time frame: 13 DAYS

Secondary outcomes

  1. POSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]

    Notification-level positive predictive value (PPV) with AF by ambulatory ECG at the time of any tachogram comprising the notification.

    Time frame: 13 DAYS

  2. TACHOGRAM ALERT SENSITIVITY [IRNF]

    Tachogram-level sensitivity performance for tachograms comprising alerts.

    Time frame: 13 DAYS

  3. TACHOGRAM ALERT SPECIFICITY [IRNF]

    Tachogram-level specificity performance for tachograms comprising alerts.

    Time frame: 13 DAYS

  4. Tachogram Alert False Positive Rate [IRNF]

    Tachogram-level False Positive rate performance for tachograms comprising alerts.

    Time frame: 13 DAYS

  5. Tachogram Alert Positive Predictive Value [IRNF]

    Tachogram-level Positive Predictive value performance for tachograms comprising alerts.

    Time frame: 13 DAYS

  6. Tachogram Alert Negative Predictive Value [IRNF]

    Tachogram-level Negative Predictive value performance for tachograms comprising alerts.

    Time frame: 13 DAYS

  7. TACHOGRAM SENSITIVITY [IRNF]

    Tachogram-level sensitivity performance for all generated tachograms.

    Time frame: 13 DAYS

  8. TACHOGRAM SPECIFICITY [IRNF]

    Tachogram-level specificity performance for all generated tachograms.

    Time frame: 13 DAYS

  9. TACHOGRAM FALSE POSITIVE RATE [IRNF]

    Tachogram-level false positive rate performance for all generated tachograms.

    Time frame: 13 DAYS

  10. TACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF]

    Tachogram-level positive predictive value performance for all generated tachograms.

    Time frame: 13 DAYS

  11. TACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF]

    Tachogram-level negative predictive value performance for all generated tachograms.

    Time frame: 13 DAYS

  12. TACHOGRAM SENSITIVITY [AFBF]

    Sensitivity of tachograms for the identification of AF by ambulatory ECG.

    Time frame: 13 days

  13. TACHOGRAM SPECIFICITY [AFBF]

    Specificity of tachograms for the identification of AF by ambulatory ECG.

    Time frame: 13 days

  14. TACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF]

    Positive Predictive Value of tachograms for the identification of AF by ambulatory ECG.

    Time frame: 13 days

  15. TACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF]

    Negative Predictive Value of tachograms for the identification of AF by ambulatory ECG.

    Time frame: 13 days

  16. DAY-SPECIFIC AF BURDEN ESTIMATE [AFBF]

    Day-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific day of the week.

    Time frame: 13 DAYS

  17. FOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF]

    Four-hour segment-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific four-hour segment of a day

    Time frame: 13 DAYS

07

Results

Posted Aug 24, 2022

Participant flow

Participant flow — Overall Study
MilestoneCOHORT 1COHORT 2COHORT 3COHORT 4
Started788236647
Completed706430445
Not completed818622

Outcome measures

PrimarySENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]

Sensitivity of the irregular rhythm notification for the identification of persons with AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Sensitivity is defined as the percentage of subjects exhibiting AF on the ambulatory ECG who also received an irregular rhythm notification concordant with at least one episode of AF.

Time frame:
13 DAYS
Reported as:
Number · percentage of participants
SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]
percentage of participantsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]NA—NANA88.6
PrimarySPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF]

Specificity of the lack of irregular rhythm notification for the identification of persons without AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Specificity is defined as the percentage of subjects not exhibiting AF on the ambulatory ECG who also did not receive any irregular rhythm notifications.

Time frame:
13 DAYS
Reported as:
Number · percentage of participants
SPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF]
percentage of participantsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
SPECIFICITY OF LACK OF IRREGULAR RHYTHM NOTIFICATIONS FEATURE [IRNF]NA—NANA99.3
PrimaryWEEKLY ATRIAL FIBRILLATION BURDEN FEATURE ESTIMATE [AFBF]

Weekly AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during wrist device wear over the prior 7 consecutive days. The weekly AF burden was estimated by both the reference device and the algorithm and reported using the Bland-Altman limits of Agreement.

Time frame:
13 DAYS
Reported as:
Number · Bland-Altman Limits of Agreement
WEEKLY ATRIAL FIBRILLATION BURDEN FEATURE ESTIMATE [AFBF]
Bland-Altman Limits of AgreementCOHORT 3COHORT 4Overall
Lower Limit of Agreement (%)NANA-11.4
Upper Limit of Agreement (%)NANA12.8
SecondaryPOSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]

Notification-level positive predictive value (PPV) with AF by ambulatory ECG at the time of any tachogram comprising the notification.

Time frame:
13 DAYS
Reported as:
Number · percentage of notifications
POSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]
percentage of notificationsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
POSITIVE PREDICTIVE VALUE OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF]——NANA100
SecondaryTACHOGRAM ALERT SENSITIVITY [IRNF]

Tachogram-level sensitivity performance for tachograms comprising alerts.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM ALERT SENSITIVITY [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM ALERT SENSITIVITY [IRNF]——NANA95.05
SecondaryTACHOGRAM ALERT SPECIFICITY [IRNF]

Tachogram-level specificity performance for tachograms comprising alerts.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM ALERT SPECIFICITY [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM ALERT SPECIFICITY [IRNF]——NANA0
SecondaryTachogram Alert False Positive Rate [IRNF]

Tachogram-level False Positive rate performance for tachograms comprising alerts.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
Tachogram Alert False Positive Rate [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
Tachogram Alert False Positive Rate [IRNF]——NANA100
SecondaryTachogram Alert Positive Predictive Value [IRNF]

Tachogram-level Positive Predictive value performance for tachograms comprising alerts.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
Tachogram Alert Positive Predictive Value [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
Tachogram Alert Positive Predictive Value [IRNF]——NANA99.83
SecondaryTachogram Alert Negative Predictive Value [IRNF]

Tachogram-level Negative Predictive value performance for tachograms comprising alerts.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
Tachogram Alert Negative Predictive Value [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
Tachogram Alert Negative Predictive Value [IRNF]——NANA0
SecondaryTACHOGRAM SENSITIVITY [IRNF]

Tachogram-level sensitivity performance for all generated tachograms.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM SENSITIVITY [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM SENSITIVITY [IRNF]NA—NANA85.5
SecondaryTACHOGRAM SPECIFICITY [IRNF]

Tachogram-level specificity performance for all generated tachograms.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM SPECIFICITY [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM SPECIFICITY [IRNF]NA—NANA99.9
SecondaryTACHOGRAM FALSE POSITIVE RATE [IRNF]

Tachogram-level false positive rate performance for all generated tachograms.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM FALSE POSITIVE RATE [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM FALSE POSITIVE RATE [IRNF]NA0.05NANA0.22
SecondaryTACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF]

Tachogram-level positive predictive value performance for all generated tachograms.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM POSITIVE PREDICTIVE VALUE [IRNF]——NANA99.8
SecondaryTACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF]

Tachogram-level negative predictive value performance for all generated tachograms.

Time frame:
13 DAYS
Reported as:
Number · percentage of tachograms
TACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF]
percentage of tachogramsCOHORT 1COHORT 2COHORT 3COHORT 4Overall
TACHOGRAM NEGATIVE PREDICTIVE VALUE [IRNF]NA—NANA77.9
SecondaryTACHOGRAM SENSITIVITY [AFBF]

Sensitivity of tachograms for the identification of AF by ambulatory ECG.

Time frame:
13 days
Reported as:
Number · percentage of tachograms
TACHOGRAM SENSITIVITY [AFBF]
percentage of tachogramsCOHORT 3COHORT 4Overall
TACHOGRAM SENSITIVITY [AFBF]NANA92.6
SecondaryTACHOGRAM SPECIFICITY [AFBF]

Specificity of tachograms for the identification of AF by ambulatory ECG.

Time frame:
13 days
Reported as:
Number · percentage of tachograms
TACHOGRAM SPECIFICITY [AFBF]
percentage of tachogramsCOHORT 3COHORT 4Overall
TACHOGRAM SPECIFICITY [AFBF]NANA98.8
SecondaryTACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF]

Positive Predictive Value of tachograms for the identification of AF by ambulatory ECG.

Time frame:
13 days
Reported as:
Number · percentage of tachograms
TACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF]
percentage of tachogramsCOHORT 3COHORT 4Overall
TACHOGRAM POSITIVE PREDICTIVE VALUE [AFBF]NANA96.7
SecondaryTACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF]

Negative Predictive Value of tachograms for the identification of AF by ambulatory ECG.

Time frame:
13 days
Reported as:
Number · percentage of tachograms
TACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF]
percentage of tachogramsCOHORT 3COHORT 4Overall
TACHOGRAM NEGATIVE PREDICTIVE VALUE [AFBF]NANA97.1
SecondaryDAY-SPECIFIC AF BURDEN ESTIMATE [AFBF]

Day-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific day of the week.

Time frame:
13 DAYS
Reported as:
Number · percent of iterations achieving success
DAY-SPECIFIC AF BURDEN ESTIMATE [AFBF]
percent of iterations achieving successCOHORT 3COHORT 4Overall
DAY-SPECIFIC AF BURDEN ESTIMATE [AFBF]NANA62.5
SecondaryFOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF]

Four-hour segment-specific AF burden estimate defined as the percentage of time a subject is in Atrial Fibrillation during a specific four-hour segment of a day

Time frame:
13 DAYS
Reported as:
Number · percent of iterations achieving success
FOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF]
percent of iterations achieving successCOHORT 3COHORT 4Overall
FOUR-HOUR SEGMENT SPECIFIC AF BURDEN ESTIMATE [AFBF]NANA99.95

Adverse events

Collected over 3.5 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COHORT 10/78 (0%)0/78 (0%)3/78 (3.8%)
COHORT 20/82 (0%)0/82 (0%)11/82 (13.4%)
COHORT 30/366 (0%)7/366 (1.9%)46/366 (12.6%)
COHORT 40/47 (0%)0/47 (0%)3/47 (6.4%)
Most frequent serious events
Most frequent serious events
EventCOHORT 1COHORT 2COHORT 3COHORT 4
Arteriosclerosis coronary arteryCardiac disorders0/780/821/3660/47
HypercalcaemiaMetabolism and nutrition disorders0/780/821/3660/47
COVID-19 pneumoniaInfections and infestations0/780/821/3660/47
SepsisInfections and infestations0/780/821/3660/47
Metabolic encephalopathyNervous system disorders0/780/821/3660/47
Angina pectorisCardiac disorders0/780/821/3660/47
Dementia/AstheniaNervous system disorders0/780/821/3660/47
Sinus node dysfunctionCardiac disorders0/780/821/3660/47
Most frequent other events
Most frequent other events
EventCOHORT 1COHORT 2COHORT 3COHORT 4
Dermatitis ContactSkin and subcutaneous tissue disorders3/7811/8246/3663/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)COHORT 1COHORT 2COHORT 3COHORT 4Total
<=18 years00000
Between 18 and 65 years604514414263
>=65 years183722233310
Age, Continuous
Age, Continuous(years)COHORT 1COHORT 2COHORT 3COHORT 4Total
Mean49.2 ± 16.6861.2 ± 15.0765.4 ± 11.7970.0 ± 8.8563.0 ± 14.09
Sex: Female, Male
Sex: Female, Male(Participants)COHORT 1COHORT 2COHORT 3COHORT 4Total
Female405318014287
Male382918633286
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)COHORT 1COHORT 2COHORT 3COHORT 4Total
Hispanic or Latino18117238
Not Hispanic or Latino608134945535
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)COHORT 1COHORT 2COHORT 3COHORT 4Total
American Indian or Alaska Native20215
Asian01214
Native Hawaiian or Other Pacific Islander00000
Black or African American19727457
White577433041502
More than one race00505
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)COHORT 1COHORT 2COHORT 3COHORT 4Total
United States788236647573
08

Study locations

4 sites
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • American Health Network of Indiana Llc
    Avon, Indiana 46123, United States
  • Heartland Cardiology Webb
    Wichita, Kansas 67226, United States
  • Healtheast
    Saint Paul, Minnesota 55012, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2021, 5 months.

Results were first posted in Aug 2022, 1 year 4 months after primary completion.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 5 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Jan 7, 2021
StartActual
Nov 16, 2020
Primary completionActual
Apr 19, 2021
CompletionActual
Dec 17, 2021
Results first posted
Aug 24, 2022
Last update
Aug 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04699812
Lead sponsor
Apple Inc.
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Nov 16, 2020
Primary completion
Apr 19, 2021
Completion
Dec 17, 2021
Results posted
Aug 24, 2022
Last update
Aug 24, 2022

Study contacts

David Tsay, MD, PhD
study director · Apple Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion